Federal Register / Vol. 72, No. 89 / Wednesday, May 9, 2007 / Notices 26415 

1490–1497). Methods of use claims are 

directed to treatments preventing the 

inflammatory response of colitis by 

modulating IL–13 and NKT cell activity 

and to methods for screening for 

therapeutic compounds effective for 

colitis. 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR 404.7. The prospective 

exclusive license may be granted unless, 

within 60 days from the date of this 

published Notice, NIH receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR 404.7. 

Properly filed competing applications 

for a license filed in response to this 

notice will be treated as objections to 

the contemplated license. Comments 

and objections submitted in response to 

this notice will not be made available 

for public inspection, and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: April 30, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–8892 Filed 5–8–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of Biotechnology Activities; 

Recombinant DNA Research: 

Proposed Actions Under the NIH 

Guidelines for Research Involving 

Recombinant DNA Molecules (NIH 

Guidelines) 

ACTION: Notice of consideration of 

proposed actions under the NIH 

Guidelines. 

SUMMARY: Proposals to conduct research 

involving the deliberate transfer of a 

tetracycline resistance trait to 

Chlamydia Trachomatis have been 

submitted to the NIH Office of 

Biotechnology Activities (OBA). The 

acquisition of this antibiotic resistance 

trait could possibly compromise the use 

of a class of antibiotics for the treatment 

of Chlamydia infections in humans. 

Under the NIH Guidelines, these 

experiments can proceed only after they 

are reviewed by the NIH Recombinant 

DNA Advisory Committee (RAC) and 

specifically approval by the NIH 

Director as Major Actions. These 

proposals will be discussed at the June 

19–21, 2007 meeting of NIH 

Recombinant DNA Advisory Committee. 

DATES: The public is encouraged to 

submit written comments on these 

proposed actions. Comments may be 

submitted to the OBA in paper or 

electronic form at the OBA mailing, fax, 

and e-mail addresses shown below 

under the heading FOR FURTHER

INFORMATION. The NIH will consider all 

comments submitted by June 15, 2007. 

Written comments submitted by May 

24, 2007 will be reproduced and 

distributed to the RAC for consideration 

at its June 19–21 meeting. In addition, 

an opportunity for public comment will 

be provided at that meeting. All written 

comments received in response to this 

notice will be available for public 

inspection at the NIH OBA office, 6705 

Rockledge Drive, Suite 750, Bethesda, 

MD 20892 (telephone, 301–496–9838), 

weekdays between the hours of 8:30 

a.m. and 5 p.m. 

FOR FURTHER INFORMATION CONTACT: 

Contact OBA by e-mail at 

oba@od.nih.gov, or telephone at 301–

496–9838, if you have questions, or 

require additional information about 

these proposed actions. Comments may 

be submitted to the same e-mail address 

or by fax at 301–496–9839 or sent by 

U.S. mail to the Office of Biotechnology 

Activities, National Institutes of Health, 

6705 Rockledge Drive, Suite 750, MSC 

7985, Bethesda, Maryland 20892–7985. 

For additional information about the 

RAC meeting at which these proposed 

actions will be deliberated, please visit 

the NIH OBA Web site at: http:// 

www4.od.nih.gov/oba/. 

SUPPLEMENTARY INFORMATION: OBA has 

received information from two 

Institutional Biosafety Committees 

regarding proposed experiments, which, 

to proceed, would require Major Actions 

under Section III–A–1–a of the NIH 

Guidelines. Under this section, if the 

deliberate transfer of a drug resistance 

trait to microorganisms could 

compromise the use of the drug to 

control disease in humans, veterinary 

medicine, or agriculture the experiment 

must be reviewed by the RAC. Dr. Dan 

Rockey and Dr. Walter Stamm (at 

Oregon State University and the 

University of Washington, respectively), 

are proposing to develop a genetic 

transformation system to study the 

pathogenesis of Chlamydia trachomatis, 

a human pathogen that is a leading 

cause of sexually transmitted disease 

worldwide and, mostly in the 

developing world, a preventable cause 

of blindness. Per the investigators, the 

lack of genetic tools to study the 

mechanisms of pathogenesis in these 

obligate intracellular bacterial parasites 

hinders research. The recent discovery 

of naturally occurring tetracycline 

resistant strains of C. suis (a swine 

pathogen) may provide the necessary 

genetic elements to develop such a 

transformation system. To accomplish 

this goal, experiments are planned to 

transfer tetracycline resistance from C. 

suis into C. trachomatis (a human 

pathogen). It is asserted that success in 

these proposed studies will lead to 

opportunities for ‘‘rapid developments 

in our understanding of chlamydial 

biology.’’ The investigators are 

proposing to perform these experiments 

under Biosafety Level 2 containment. 

Background information may be 

obtained by contacting NIH OBA via email at oba@od.nih.gov. Alternatively, 

information is available on the OBA 

Web site at http://www4.od.nih.gov/oba/ 

rac/latestnewsrac.htm. 

Dated: May 3, 2007. 

Amy P. Patterson, 

Director, Office of Biotechnology Activities, 

National Institutes of Health. 

[FR Doc. E7–8900 Filed 5–8–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

[USCG–2007–28034] 

Chemical Transportation Advisory 

Committee; Vacancies 

AGENCY: Coast Guard, DHS. 

ACTION: Request for applications. 

SUMMARY: The Coast Guard is seeking 

applications for appointment to 

membership on the Chemical 

Transportation Advisory Committee 

(CTAC). CTAC advises, consults with, 

and makes recommendations to the 

Coast Guard on matters relating to the 

safe and secure transportation and 

handling of hazardous materials in bulk 

on U.S.-flag vessels in U.S. ports and 

waterways. 

DATES: Application forms should reach 

the Coast Guard on or before August 31, 

2007. 

ADDRESSES: You may request an 

application form by writing to 

Commandant (CG–3PSO–3), U.S. Coast 

Guard, 2100 Second Street SW., 

Washington, DC 20593–0001; by calling 

(202) 372–1425/1422; or by faxing (202) 

372–1926. Submit application forms to 

the same address. This notice and the 

application form are available on the 

Internet at http://dms.dot.gov. The 

application form is also available at 


sroberts on PROD1PC70 with NOTICES
26416 Federal Register / Vol. 72, No. 89 / Wednesday, May 9, 2007 / Notices 

http://www.uscg.mil/hq/g-m/advisory/ 

ctac/ctac.htm. 

FOR FURTHER INFORMATION CONTACT: 

Commander Richard J. Raksnis, 

Executive Director of CTAC, or Ms. Sara 

S. Ju, Assistant to the Executive 

Director, telephone (202) 372–1425/ 

1422, fax (202) 372–1926. 

SUPPLEMENTARY INFORMATION: The 

Chemical Transportation Advisory 

Committee (CTAC) is an advisory 

committee constituted under the 

Federal Advisory Committee Act, 5 

U.S.C. App. 2. It advises, consults with, 

and makes recommendations to the 

Commandant through the Assistant 

Commandant for Prevention on matters 

relating to the safe and secure 

transportation and handling of 

hazardous materials in bulk on U.S.-flag 

vessels in U.S. ports and waterways. 

The advice and recommendations of 

CTAC also assist the U.S. Coast Guard 

in formulating the position of the 

United States on hazardous material 

transportation issues prior to meetings 

of the International Maritime 

Organization. 

CTAC meets at least once a year, 

usually twice a year, at Coast Guard 

Headquarters in Washington, DC, or in 

another location. CTAC’s 

subcommittees and working groups may 

meet to perform specific assignments as 

required. 

The Coast Guard will consider 

applications for eight positions that 

expire on December 31, 2007. To be 

eligible, applicants should have 

experience associated with, and 

represent the viewpoints of, the 

following areas associated with marine 

chemical transportation: Chemical 

manufacturing, vessel design and 

construction, safety and security, 

marine environmental protection, or 

marine handling or transportation of 

chemicals. Each member serves for a 

term of 3 years. Some members may 

serve consecutive terms. All members 

serve at their own expense, and receive 

no salary, reimbursement of travel 

expenses, or other compensation from 

the Federal Government. While CTAC 

Charter expires on July 5, 2007, 

appointments will be made in 

anticipation of a renewal of the CTAC 

Charter. 

In support of the policy of the 

Department of Homeland Security on 

gender and ethnic diversity, the Coast 

Guard encourages applications from 

qualified women and members of 

minority groups. 

Dated: April 26, 2007. 

J.G. Lantz, 

Director of National and International 

Standards, Assistant Commandant for 

Prevention. 

[FR Doc. E7–8856 Filed 5–8–07; 8:45 am] 

BILLING CODE 4910–15–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Transportation Security Administration 

Extension of Agency Information 

Collection Activity Under OMB Review: 

Department of Homeland Security 

Traveler Redress Inquiry Program 

(DHS TRIP) 

AGENCY: Transportation Security 

Administration, DHS. 

ACTION: Notice. 

SUMMARY: This notice announces that 

the Transportation Security 

Administration (TSA) has forwarded the 

Information Collection Request (ICR) 

abstracted below to the Office of 

Management and Budget (OMB) for 

review and approval of an extension of 

the currently approved collection under 

the Paperwork Reduction Act. The ICR 

describes the nature of the information 

collection and its expected burden. TSA 

published a Federal Register notice, 

with a 60-day comment period soliciting 

comments, of the following collection of 

information on January 5, 2007, 72 FR 

576. The collection involves the 

submission of identifying and travel 

experience information by individuals 

requesting redress through DHS TRIP. 

DATES: Send your comments by June 8, 

2007. A comment to OMB is most 

effective if OMB receives it within 30 

days of publication. 

ADDRESSES: Interested persons are 

invited to submit written comments on 

the proposed information collection to 

the Office of Information and Regulatory 

Affairs, Office of Management and 

Budget. Comments should be addressed 

to Nathan Lesser, Desk Officer, 

Department of Homeland Security/TSA, 

and sent via electronic mail to 

oira_submission@omb.eop.gov or faxed 

to (202) 395–6974. 

FOR FURTHER INFORMATION CONTACT: 

Joanna Johnson, Program Analyst, Office 

of Communications, Business 

Management Office, Operational Process 

and Technology, TSA–11, 

Transportation Security Administration, 

701 South 12th Street, Arlington, VA 

22202–4220; telephone (571) 227–3651; 

facsimile (571) 227–3885. 

SUPPLEMENTARY INFORMATION: 

Comments Invited 

In accordance with the Paperwork 

Reduction Act of 1995 (44 U.S.C. 3501 

et seq.), an agency may not conduct or 

sponsor, and a person is not required to 

respond to, a collection of information 

unless it displays a valid OMB control 

number. The ICR documentation is 

available at www.reginfo.gov. Therefore, 

in preparation for OMB review and 

approval of the following information 

collection, TSA is soliciting comments 

to—

(1) Evaluate whether the proposed 

information requirement is necessary for 

the proper performance of the functions 

of the agency, including whether the 

information will have practical utility; 

(2) Evaluate the accuracy of the 

agency’s estimate of the burden; 

(3) Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

(4) Minimize the burden of the 

collection of information on those who 

are to respond, including using 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

Information Collection Requirement 

Title: Department of Homeland 

Security Traveler Redress Inquiry 

Program (DHS TRIP). 

Type of Request: Extension of a 

currently approved collection. 

OMB Control Number: 1652–0044. 

Forms(s): Traveler Inquiry Form, 

Third Party Consent Form. 

Affected Public: Traveling public. 

Abstract: The Rice-Chertoff Initiative 

(RCI) Department of Homeland Security. 

Traveler Redress Inquiry Program (DHS 

TRIP) was developed as a voluntary 

program by DHS to provide a one-stop 

mechanism for individuals to request 

redress who believe they have been: (1) 

Denied or delayed boarding; (2) denied 

or delayed entry into or departure from 

the United States at a port of entry; or 

(3) identified for additional (secondary) 

screening at our Nation’s transportation 

hubs, including airports, seaports, train 

stations and land borders. The DHS 

TRIP office will be located at, and 

managed by, TSA. In order for 

individuals to request redress, they are 

asked to provide identifying 

information, as well as details of the 

travel experience. Individuals can do so 

online at http://www.dhs.gov/trip. DHS 

TRIP then passes the information to the 

relevant DHS component to process the 

request, as appropriate. This collection 

serves to distinguish individuals from 

an actual individual on any watch list 

used by DHS, and it helps streamline 


sroberts on PROD1PC70 with NOTICES